Holen Sie sich die Stockscreener-App
4.71
3.58%
-0.175
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Growth Value: Can Recursion Pharmaceuticals Inc stock maintain growth trajectoryQuarterly Portfolio Report & AI Enhanced Trading Alerts - BỘ NỘI VỤ
Recursion pharma CEO Gibson sells $185,200 in shares - Investing.com
Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 220,000 Shares of Stock - MarketBeat
Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? - sharewise.com
Jim Cramer: This Health Care Stock Has Been 'Horrendous' - Benzinga
Recursion Pharmaceuticals Registers Resale of 7 Million Shares - MSN
Recursion Pharmaceuticals: Is It the Right Time to Buy? - StocksToTrade
Cramer's Lightning Round: Recursion Pharmaceuticals 'has been horrendous' - CNBC
Recursion Pharmaceuticals Insider Sold Shares Worth $961,400, According to a Recent SEC Filing - marketscreener.com
Recursion Pharmaceuticals: Is This Just The Beginning? - timothysykes.com
A Look At The Fair Value Of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - 富途牛牛
RECURSION PHARMACEUTICALS INC (RXRX.MX) Q1 FY2025 earnings call transcript - Yahoo Finance
Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and Clinical Data Readout - Quiver Quantitative
Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade - InvestorPlace
Costco, AMD, Recursion Pharmaceuticals, Cipher Mining And Snowflake: Why These 5 Stocks Are On Investors' Radars Today - AOL.com
Capital Fund Management S.A. Has $3.65 Million Stock Holdings in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Can Recursion Pharmaceuticals Inc. stock continue upward trendQuarterly Profit Report & Advanced Swing Trade Entry Alerts - Newser
Is Recursion Pharmaceuticals Inc. stock attractive for hedge fundsMarket Trend Review & Verified Technical Signals - Newser
Quadrature Capital Ltd Takes Position in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion to Host Webinar on Tupelo Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis on Dec. 8 - TradingView
Recursion to present updated FAP trial data of REC-4881 in webinar - Investing.com Australia
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 - The Manila Times
Recursion to Present Updated Clinical Readout from TUPELO Trial of REC-4881 in Familial Adenomatous Polyposis at December 8 Webinar - Quiver Quantitative
Recursion Pharmaceuticals (RXRX): Valuation Insights Following New Partnerships and Better-Than-Expected Quarterly Results - Sahm
Will Recursion (RXRX) Share Registration Deepen Its Tech Partnerships or Signal a Shift in Strategy? - simplywall.st
Recursion Pharmaceuticals Gains Traction with Strategic Developments - timothysykes.com
Recursion Pharmaceuticals’ Advances Boost Market Confidence - timothysykes.com
Tangible book value per share of Recursion Pharmaceuticals, Inc. Class A – BIVA:RXRX - TradingView
Geode Capital Management LLC Acquires 1,332,428 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
XTX Topco Ltd Buys New Shares in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock - AOL.com
Rockefeller Capital Management L.P. Sells 170,691 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
RXRX SEC FilingsRecursion Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
CFO Taylor Surrenders 2,271 Of Recursion Pharmaceuticals Inc [RXRX] - TradingView
[Form 4] RECURSION PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Recursion Pharmaceuticals Stock (RXRX) Opinions on Exscientia Merger and Partnerships - Quiver Quantitative
Recursion Pharmaceuticals registers 7.1 million shares for Tempus AI resale By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals registers 7.1 million shares for Tempus AI resale - Investing.com
Recursion Pharmaceuticals Registers Resale of Tempus Shares - TradingView
[8-K] RECURSION PHARMACEUTICALS, INC. Reports Material Event | RXRX SEC FilingForm 8-K - Stock Titan
Form 424B7 RECURSION PHARMACEUTICAL - StreetInsider
RXRX files prospectus for Tempus AI resale of 7.09M shares - Stock Titan
Is the Market Bullish or Bearish on Recursion Pharmaceuticals Inc? - Benzinga
A Look at Recursion Pharmaceuticals’s Valuation Following New CEO, Narrowed Losses, and Milestone Partnership Payment - Yahoo Finance
Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today - MSN
Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? - The Globe and Mail
Recursion Pharmaceuticals (RXRX): Evaluating Valuation After Fresh Leadership, Pharma Partnerships, and Market Optimism - simplywall.st
Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025 - ts2.tech
Top Biotech Stocks To Watch TodayNovember 21st - MarketBeat
Recursion (RXRX) Jumps 8% on Bargain-Hunting - Finviz
1.44%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):